Abstracts

48 – Long-Acting InSTI Strategies: Understanding the Risks for Failure and Resistance

Long-acting injectables (LAI) represents one of the most significant advances in antiretroviral therapy in recent years, offering durable suppression for PLWH who find daily oral medications challenging. Confirmed virological failure (CVF) is a low-incidence (1.4% over 152 weeks) but high-consequence event, with almost all developing drug-resistant mutations. This is in contrast to daily oral INSTI-based…

20 – Immune Responses During Viral Rebound

The objectives of this talk are to: (1) define different patterns of HIV rebound (i.e., categories of post-ART control), (2) review examples of effective immune responses against HIV, focusing on immune mechanisms that have been implicated in post-ART control, and (3) discuss lessons learned about immune responses to rebound from recent ATI trials, including the…

21 – Advanced HIV Disease in Children

In 2025, late diagnosis of HIV in children continues to be a significant global concern, with many presenting with advanced HIV disease (AHD). This issue contributes to a considerable number of hospital admissions, particularly among infants, due to acute conditions such as pneumonia, sepsis, and diarrhea. These acute illnesses are frequently accompanied by important by…

32 – The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation

HIV-1 persists in a mostly latent state within blood and tissues during suppressive ART. Proviral integration sites may play a critical role in the establishment and maintenance of this latent reservoir. Understanding the landscape of proviral integration is essential for deciphering the mechanisms behind HIV-1 latency and reactivation. Recent studies have shed light on the…

5 – Advances in CRISPR-Cas Editing Methods and Their Use in Virology and Immunology

Humanized mouse models, immunodeficient mice transplanted with human cells/tissues, have been used by HIV researchers for over 30 years to study aspects of HIV infection (e.g. transmission, pathogenesis, and persistence) and to perform efficacy testing of novel prevention, treatment, and cure approaches. This presentation will introduce the most commonly used humanized mouse models for HIV…

7 – Hepatitis B in the Gray Zone: Personalizing Treatment and Monitoring

Hepatitis B remains a significant cause of liver disease and remains the leading cause of hepatocellular carcinoma worldwide.  Effective therapy for hepatitis B is available, and nucleos(t)ide analogs (NAs) suppress hepatitis B DNA levels and normalize ALT levels. Long-term treatment can lead to reduction in necroinflammatory activity, with potential improvement in fibrosis or reduction in…